載入...
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
INTRODUCTION: Lenalidomide is an active agent that was approved for use in the EU in 2015 as a first-line therapy for previously untreated, non-transplant eligible multiple myeloma patients. Our objective was to assess the cost impact of lenalidomide when selected as a first-line treatment for trans...
Na minha lista:
| 發表在: | Oncol Ther |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer Healthcare
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5488111/ https://ncbi.nlm.nih.gov/pubmed/28680953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-016-0037-8 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|